Johnson & Johnson

Equities

JNJ

US4781601046

Pharmaceuticals

Real-time Estimate Cboe BZX 10:44:30 2024-03-28 am EDT 5-day change 1st Jan Change
158.5 USD +0.36% Intraday chart for Johnson & Johnson +1.74% +1.10%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Johnson & Johnson Welcomes US Judge's Ruling on New Chance to Contest Evidence in Talc Case MT
J&J can contest evidence linking its talc to cancer, US judge rules RE
J&J gets new opportunity to contest evidence linking talc to cancer RE
Global markets live: Apple, UBS, Microstrategy, Merck, Amazon... Our Logo
J&J: Fast Track designation for nipocalimab CF
National Legal and Policy Center Files Exempt Solicitation Statement with Securities and Exchange Commission CI
Sector Update: Health Care Stocks Advance Late Afternoon MT
Sector Update: Health Care MT
Johnson & Johnson in Talks to Acquire Shockwave Medical MT
Johnson & Johnson in Talks to Acquire Shockwave Medical MT
Johnson & Johnson Reportedly in Talks to Acquire Shockwave Medical MT
Johnson & Johnson considers deal for Shockwave Medical, WSJ reports RE
Johnson & Johnson Gets FDA Fast-Track for Rare Pregnancy-Related Disease DJ
U.S. FDA Grants Johnson & Johnson's Nipocalimab Fast Track Designation CI
Johnson & Johnson Reportedly Considers Deal for Shockwave Medical CI
Johnson & Johnson Gets FDA Approval for Pulmonary Arterial Hypertension Pill DJ
Johnson & Johnson Announces U.S. Food and Drug Administration Approves Opsynvi as the First and Only Once-Daily Single-Tablet Combination Therapy for Patients with Pulmonary Arterial Hypertension CI
US FDA classifies recall of Abiomed's blood pumps as most serious RE
J&J: FDA approval for Edurant Ped in HIV CF
Clearside Biomedical Names Victor Chong Chief Medical Officer MT
J&J: will present data in lung cancer CF
Formycon, Fresenius Kabi Sign Settlement Deal with Johnson & Johnson for Ustekinumab Biosimilar MT
Fresenius Settles With Johnson & Johnson to Market Stelara Alternative DJ
Legend Biotech, Johnson & Johnson Cancer Therapy Wins FDA Advisory Panel Nod MT
Sector Update: Health Care Stocks Ease Late Afternoon MT
Chart Johnson & Johnson
More charts
Johnson & Johnson is one of the world's leading producers of healthcare products. Net sales break down by family of products as follows: - pharmaceutical products (55.4%): drugs intended for the treatment of cardiovascular diseases, oncological diseases, gastro-intestinal illnesses, infectious, immunological, neurological, dermatological diseases, etc.; - medical products and equipment (28.9%): diagnostic systems, orthopedic and gynecological equipment, surgical materials, etc. for use by healthcare professionals; - consumer health products (15.7%): OTC drugs (Tylenol, Sudafed, Benadryl, Zyrtec, Motrin, Nicorette and other brands), health and beauty products (Aveeno, Clean & Clear, Dr. CI:Labo, Neutrogena and OGX), baby care products (Johnson's and Aveeno Baby), oral care products (Listerine), feminine hygiene products (Stayfree and Carefree and o.b.), wound care products (Band-Aid and Neosporin) etc. At the end of 2022, Johnson & Johnson has 89 manufacturing facilities located in the United States (28), North America (9), Europe (27), Africa and Asia/Pacific (25). Net sales are distributed geographically as follows: the United States (51.2%), Europe (24.7%), Asia/Pacific and Africa (17.7%) and other (6.4%).
Calendar
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C+
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
22
Last Close Price
158 USD
Average target price
175.4 USD
Spread / Average Target
+11.05%
Consensus
  1. Stock
  2. Equities
  3. Stock Johnson & Johnson - Nyse
  4. News Johnson & Johnson
  5. Street Color: CDC Reportedly Investigating Two New Clotting Cases After Johnson & Johnson Shots Resumed Friday